Zhou 2014 NCCN-IPI for DLBCL in the rituximab era: age (≤40 0, 41–60 1, 61–75 2, ≥76 3), LDH/ULN (≤1 0, >1–3 1, >3 2), Ann Arbor III or IV 1, major-organ extranodal (bone marrow, CNS, liver/GI tract, or lung) 1, ECOG ≥2 1; max 8. Low 0–1, low_intermediate 2–3, high_intermediate 4–5, high 6–8. Deterministic published score; not a DLBCL diagnosis or treatment choice; not Shipp IPI, not R-IPI, not CNS-IPI. magent does not assay LDH or stage lymphoma.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.005000 USDC | 0x836B...9Ee2 |